Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Amedisys (AMED) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -7.26% and 3.41%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Amedisys (AMED) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.
3 Stocks to Watch From the Pandemic-Hit Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. AMED, ADUS and HNGR are well poised to gain from the prospects.
Here's Why Investors Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
Amedisys (AMED) Q2 Earnings Beat Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 19.51% and 4.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Encompass Health (EHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Amedisys (AMED) Q2 Earnings Expected to Decline
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care
by Zacks Equity Research
Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.
Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range
by Zacks Equity Research
Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.
Are Options Traders Betting on a Big Move in Amedisys (AMED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.
Amedisys (AMED) Down 11% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investors are optimistic about the robust performances of Amedisys' (AMED) Home Health and Hospice segments.
Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays
by Zacks Equity Research
Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.
Amedisys (AMED) Q1 Earnings Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 10.81% and 2.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Amedisys (AMED) Stock For Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.
Why Is Amedisys (AMED) Up 13.2% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 9th
by Zacks Equity Research
AGESY, AMED, and APAM have been added to the Zacks Rank #5 (Strong Sell) List on March 9, 2022.
New Strong Sell Stocks for March 4th
by Zacks Equity Research
AMED, CACC, and EXPO have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2022
Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.
Amedisys (AMED) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 0.86% and 0.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.60% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 29th
by Zacks Equity Research
B, FPI, CGNX, AMED, and FSUGY have been added to the Zacks Rank #5 (Strong Sell) List on December 29, 2021.